Abcam founder seeks to block $5.7 billion Danaher deal
Reuters
Published Sep 14, 2023 08:34AM ET
Updated Sep 14, 2023 01:46PM ET
(Reuters) -Abcam Plc founder Jonathan Milner on Thursday said he would vote against medical tools supplier Danaher (NYSE:DHR)'s proposed $5.7 billion acquisition of the company, as it undervalues the protein consumables maker.
Danaher's offer price of $24 per share "falls significantly short of its (Abcam's) inherent worth", Milner said.
Milner, who owns a 6.14% stake in the company, has been pushing to refresh its board while calling for improvements in governance to restore the company's share price for a fair valuation for a buyout offer. The stock has gained about 47% this year.
Abcam has come under pressure from Milner and activist shareholders including hedge fund Starboard Value LP to sell itself.
Milner, who served Abcam as CEO from 1999 to 2014 and later as deputy chairman from 2015 to 2020, in June had appealed to shareholders to elect him as executive chairman, while calling for the removal of Peter Allen, Michael Baldock, and Sally Crawford as directors of the company.
On Thursday, Milner said he would formally request the board for a general meeting to replace members including chairman, chief executive and chief financial officer.
Abcam considers it "surprising" that Milner is taking steps to oppose the deal which appears to be an attempt to create confusion for shareholders ahead of voting on the transaction, a company spokesperson said.
William Blair analyst Matt Larew said that though the founder's announcement injects more uncertainty, the deal is more likely to close and he does not expect another bidder to emerge.
Cambridge, England-based Abcam manufactures and supplies so-called protein consumables such as antibodies, reagents used for medical research.
Danaher said on Thursday it is committed to Abcam’s current geographic presence, with its headquarters in the UK.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.